SCHEMBL6783165

SCHEMBL6783165

CC(C)(C)OC(=O)NC1CC1.O=C(O)C1CC(=O)N(O)C1=O

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BTK Q06187 1/20 0.48
KDM1A O60341 1/20 0.45
MAOB P27338 1/20 0.45
CTSK P43235 2/20 0.42
KMT2A Q03164 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
GAA P10253 2/20 0.41
DRD2 P14416 4/20 0.41
KCNA3 P22001 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
CKS1B P61024 1/20 0.39
SKP1 P63208 1/20 0.39
SKP2 Q13309 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
DRD3 P35462 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5259587 0.87 BTK (0.43) BTKKDM1AMAOBCTSKKMT2A
Bicarbonate SCHEMBL187492 0.77 BTK (0.62) BTKKDM1AMAOBCTSKKMT2A
SCHEMBL1406894 0.77 BTK (0.61) BTKKDM1AMAOBCTSKKMT2A
SCHEMBL3702152 0.77 BTK (0.61) BTKKDM1AMAOBCTSKKMT2A
SCHEMBL10343938 0.77 BTK (0.61) BTKKDM1AMAOBCTSKKMT2A
SCHEMBL3702157 0.77 BTK (0.61) BTKKDM1AMAOBCTSKKMT2A
Methyl Alcohol SCHEMBL28082230 0.75 BTK (0.59) BTKKDM1AMAOBCTSKKMT2A
SCHEMBL1408376 0.75 MAPT (0.35) KMT2AGAA
SCHEMBL384010 0.75 BTK (0.69) BTKKDM1AMAOBCTSKKMT2A
SCHEMBL30915791 0.75 BTK (0.69) BTKKDM1AMAOBCTSKKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed
EP-0850221-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1998-07-01 EP disclosed
WO-1997008145-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-03-06 WO disclosed